While Pliant Therapeutics and Acelyrin recently blocked ever-eager acquirer Concentra Biosciences with “poison pill” defenses ...

As the U.S. stock market experiences volatility amid tariff announcements, investors are increasingly cautious about their next moves. Penny stocks, often associated with smaller or less-established ...

Allakos Inc. SAN CARLOS, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- Allakos Inc. (“Allakos”) (Nasdaq: ALLK), a biotechnology company that has been developing antibodies for the treatment of ...

Pursuant and subject to the terms of the Merger Agreement, a wholly owned subsidiary of Concentra will commence a tender offer (the“Offer”) by April 15, 2025 to acquire all outstanding shares of ...

Allakos (ALLK) has entered into a definitive merger agreement whereby Concentra Biosciences will acquire Allakos for $0.33 in cash per share of ...

Allakos on Wednesday said Concentra Biosciences, controlled by life sciences-focused investment firm Tang Capital, has agreed to pay 33 cents a share in cash for the Menlo Park, Calif., company, a 52% ...

SAN CARLOS, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- Allakos Inc. (ALLK), a biotechnology company that has been developing antibodies for the treatment of allergic, inflammatory and ...

In the tender offer transaction, shareholders of Allakos will receive $0.33 in cash per each share of Allakos common stock. Allakos insiders holding approximately 8.07% of Allakos shares have signed ...

The Ademi Firm is investigating Allakos (Nasdaq: ALLK) for possible breaches of fiduciary duty and other violations of law in its transaction with Concentra. Click here to learn how to join our ...